{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:54:55Z","timestamp":1794030895453,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.107038","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:18:40Z","timestamp":1769818720000},"page":"107038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Tolebrutinib and the FDA"],"prefix":"10.1016","volume":"107","author":[{"given":"Gavin","family":"Giovannoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Ann","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107038_bib0001","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1093\/brain\/awae013","article-title":"Imaging chronic active lesions in multiple sclerosis: a consensus statement","volume":"147","author":"Bagnato","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107038_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2020.102412","article-title":"RimNet: A deep 3D multimodal MRI architecture for paramagnetic rim lesion assessment in multiple sclerosis","volume":"28","author":"Barquero","year":"2020","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.msard.2026.107038_bib0003","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/jon.13242","article-title":"Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis","volume":"34","author":"Chen","year":"2024","journal-title":"J. Neuroimaging"},{"issue":"18","key":"10.1016\/j.msard.2026.107038_bib0004","article-title":"Low-cost point-of-care monitoring of ALT and AST is promising for faster decision making and diagnosis of acute liver injury","volume":"13","author":"Chinnappan","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.msard.2026.107038_bib0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14737175.2016.1217155","article-title":"Perception of risk and shared decision making process in multiple sclerosis","volume":"17","author":"Cocco","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.msard.2026.107038_bib0006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/ern.12.5","article-title":"Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis","volume":"12","author":"Costelloe","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.msard.2026.107038_bib0007","unstructured":"FDA, 2025. New drug application tolebrutinib tablets. URL https:\/\/download.open.fda.gov\/crl\/CRL_NDA219624_20251223.pdf. (accessed 12.23.25)."},{"key":"10.1016\/j.msard.2026.107038_bib0008","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107038_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u201creal MS","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107038_bib0009","doi-asserted-by":"crossref","first-page":"fcaf010","DOI":"10.1093\/braincomms\/fcaf010","article-title":"MRI versus relapse: optimal activity monitoring for management of progressive multiple sclerosis","volume":"7","author":"Giovannoni","year":"2025","journal-title":"Brain Commun."},{"key":"10.1016\/j.msard.2026.107038_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106403","article-title":"Is multiple sclerosis a microgliopathy?","volume":"96","author":"Hawkes","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107038_bib0011","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1191\/1352458504ms1112oa","article-title":"Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis","volume":"10","author":"Heesen","year":"2004","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107038_bib0012","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jns.2017.03.001","article-title":"Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients","volume":"376","author":"Heesen","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107038_bib0013","unstructured":"Hh, M.A.., n.d. Emirates Drug Establishment grants global first approval for \u201cTolebrutinib\u201d [WWW Document]. URL https:\/\/www.wam.ae\/en\/article\/ble2e9x-emirates-drug-establishment-grants-global-first (accessed 1.23.26)."},{"key":"10.1016\/j.msard.2026.107038_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251372752","article-title":"Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook","volume":"18","author":"Klotz","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107038_bib0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107038_bib0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s13760-018-0882-3","article-title":"Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus","volume":"118","author":"Lambert","year":"2018","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2026.107038_bib0017","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1017\/cjn.2018.325","article-title":"Goodpasture\u2019s syndrome following alemtuzumab therapy in multiple sclerosis","volume":"45","author":"Lapointe","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107038_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104701","article-title":"B cell depletion therapy does not resolve chronic active multiple sclerosis lesions","volume":"94","author":"Maggi","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2026.107038_bib0019","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/acn3.50893","article-title":"Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis","volume":"6","author":"Magliozzi","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107038_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.107012","article-title":"Real-world detection of paramagnetic rim lesions and their association with disease burden in multiple sclerosis","volume":"107","author":"Misin","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107038_bib0021","first-page":"LB1.1","article-title":"Paramagnetic rim lesions as a prognostic and predictive biomarker in the tolebrutinib phase 3 trials for disability outcomes","volume":"31","author":"Oh","year":"2025","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107038_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27010482","article-title":"Human leukocyte antigen signatures and idiosyncratic drug-induced liver injury","volume":"27","author":"Onaciu","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2026.107038_bib0023","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/bjc.2011.79","article-title":"Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care","volume":"104","author":"Peto","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.msard.2026.107038_bib0024","unstructured":"Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis [WWW Document], n.d. URL https:\/\/www.sanofi.com\/assets\/dotcom\/pressreleases\/2025\/2025-12-15-06-05-00-3205094-en.pdf (accessed 1.22.26)."},{"key":"10.1016\/j.msard.2026.107038_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.msard.2012.12.007","article-title":"To tell or not to tell? Revealing the diagnosis in multiple sclerosis","volume":"2","author":"Raphael","year":"2013","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107038_bib0026","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.27034","article-title":"Smouldering-associated worsening in multiple sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions","volume":"96","author":"Scalfari","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107038_bib0027","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1021\/acssensors.4c01482","article-title":"Signal-boosted electrochemical lateral flow immunoassay for early point-of-care detection of liver cancer biomarker","volume":"9","author":"Shi","year":"2024","journal-title":"ACS Sens."},{"key":"10.1016\/j.msard.2026.107038_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2024.110810","article-title":"Prognostic significance of paramagnetic rim lesions in multiple sclerosis: A systematic review","volume":"129","author":"Toru Asahina","year":"2024","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2026.107038_bib0029","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/clpt.2012.189","article-title":"HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review","volume":"92","author":"Yip","year":"2012","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:50:04Z","timestamp":1780415404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"alternative-id":["S221103482600074X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107038","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolebrutinib and the FDA","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107038"}}